Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

Description

This research study aims to learn more about the impact the hormone aldosterone on the heart. Primary aldosteronism is a condition where the body's adrenal glands make too much of the hormone aldosterone, which can cause high blood pressure and increase the risk of heart and kidney disease. Treatment with medications that block aldosterone can reduce that risk. This study is trying to learn whether treatment with a medication that blocks aldosterone can improve heart function in people who make too much aldosterone.

Conditions

Primary Aldosteronism, Hypertension

Talk to us

Study Overview

On this page

Study Details

Study overview

This research study aims to learn more about the impact the hormone aldosterone on the heart. Primary aldosteronism is a condition where the body's adrenal glands make too much of the hormone aldosterone, which can cause high blood pressure and increase the risk of heart and kidney disease. Treatment with medications that block aldosterone can reduce that risk. This study is trying to learn whether treatment with a medication that blocks aldosterone can improve heart function in people who make too much aldosterone.

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

Condition
Primary Aldosteronism
Intervention / Treatment

-

Contacts and Locations

Boston

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adults aged 18-85
  • * Able to provide informed consent and willing to comply with the study
  • * Able to fit safely in PET/CT scanner (weight limit 500 pounds; diameter and circumference of PET/CT scanner are 70 cm and 220 cm, respectively)
  • * Hypertension treated with at least one antihypertensive drug
  • * Cohort A: Clinically confirmed diagnosis of PA not yet treated with mineralocorticoid receptor antagonists
  • * History of MI, CABG, known cardiomyopathy (EF \<40%, hypertrophic cardiomyopathy, and/or amyloid), cardiac transplantation
  • * Contraindication or allergy to eplerenone or spironolactone
  • * Current pregnancy or breastfeeding
  • * eGFR \< 45 mL/min/1.73m2 or potassium \> 5.1 on labs within the preceding 3 months
  • * Cohort A: Planned adrenalectomy in the subsequent 6 months

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Brigham and Women's Hospital,

Study Record Dates

2027-02-28